In an article on June 7th of The Boulder County Business Report, the city of Boulder, Colorado was cited for national recognition as an innovation hub in various informal polls.

ICIG announced today changes in the management of CordenPharma, its pharmaceutical contract manufacturing business.

Visit our upcoming poster Development of a Scalable Process for CNP-22, presented by Valerie Paulsen, Principal Analytical Chemist, CordenPharma Colorado at Tides 2013, May 12 - 15 in Boston.

In a recent issue of their e-newslettter PrepLC eNews, the R&D staff at Phenomenex interviews Dr. Brad DeHoff, Director of R&D for CordenPharma Colorado, about current and future trends of the CMO industry.

International Chemical Investors Group (ICIG) kicks off €50+ million investment at PPC, a company of WeylChem Group, the fine chemicals platform of ICIG, to develop membrane-based technology. PPC is located in Thann, France.

In an article published on March 4th in Chemical & Engineering News, CordenPharma Colorado was named an approved peptide supplier to Ironwood Pharmaceuticals for their product Linaclotide: 
 

On Thursday, February 28th CordenPharma Colorado sponsored and sent 3 scientists to serve as jurors for the CordenPharma Colorado Regional Science Fair, which took place at on the University of Colorado campus in Boulder.

CordenPharma announces an expansion of manufacturing capabilities due to the recent acquisition by International Chemical Investors Group (ICIG) of Farchemia from the Tessenderlo Group, completed on December 5th, 2012.

CordenPharma Chenôve receives updated certificate of compliance to cGMP standards from the PDMA in Japan and the ANSM in France.

CordenPharma Caponago Receives Workplace Conditions Assessment (WCA) Achievement Award Enabled by Intertek.

Today Orifarm Generics announced that CordenPharma was elected as the Best Supplier in the Orifarm Generics' Supplier Evaluation 2012.

CordenPharma presents the award for the Most Effective Process Development/Scale-Up Programme at the European Outsourcing Awards on October 10th in Madrid during CPhI 2012. And the winner is....

Tessenderlo Group (NYSE Euronext: TESB) announced today that it has the intention to sell its pharmaceutical ingredients activities, Farchemia and Calaire Chimie, to International Chemical Investors Group (ICIG), a private industrial holding company. The sale concerns two production sites in France and Italy.

Today CordenPharma announced the approval of our proprietary generic drug product dossier for Paclitaxel in the reference state (Germany). With this approval CordenPharma is now open to out-licensing the generic Paclitaxel dossier with rights to register, promote and market the drug to esteemed customers in all EU territories.

CordenPharma will be Gold Sponsors of the Boulder Peptide Symposium, taking place September 26-28, 2012 at the St. Julien Hotel and Spa in Boulder, CO. Read the full story for Discounted Registration Information.

In the Boulder Daily Camera's annual list of Top 50 Largest Businesses, CordenPharma Colorado ties with Google Inc. at Number 42 ~ click here for the Daily Camera's full article.

Based on its recent analysis of the pharmaceutical contract manufacturing market, Frost & Sullivan recognises CordenPharma with the 2011 Western Europe Frost & Sullivan Award for Product Differentiation Excellence.

We are pleased to announce that on September 1, 2011 International Chemical Investors Group (ICIG) acquired a former division of Roche to join their pharmaceutical platform CordenPharma International as CordenPharma Colorado.

Luxembourg – International Chemical Investors Group (ICIG) announced that it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.